Lakshmi Pendyala, Gary Schwartz, Patrick Smith, Joseph Zdanowicz, Michael Murphy, Frederick Hausheer
文献索引:Cancer Chemother. Pharmacol. 51(5) , 376-84, (2003)
全文:HTML全文
BNP7787 (disodium 2,2'-dithio-bis-ethane sulfonate) was evaluated in a phase I clinical trial with paclitaxel and cisplatin to assess the safety and potential efficacy for preventing or reducing cisplatin- and paclitaxel-induced toxicities. During this trial the effects of BNP7787 administration on the total concentrations (oxidized plus free) of cysteine, homocysteine and GSH in plasma, free and total GSH in WBC and rate of urinary excretion of cysteine were studied. The pharmacokinetics of ultrafilterable (free, non-protein bound) platinum were also determined after cisplatin (75 mg/m(2)) treatment which followed paclitaxel (175 mg/m(2)) and BNP7787 (8.2 to 27.6 g/m(2)).Plasma thiols were measured by HPLC with fluorescence detection and platinum was measured by atomic absorption spectrophotometry.BNP7787 administration produced a significant depletion of all plasma thiols in all the patients studied. Differences were noted in the kinetics of BNP7787-induced depletion of cysteine and other thiols. A significant depletion of cysteine occurred with a time lag of about 2 h after the end of BNP7787 infusion, while a reversible depletion of GSH and homocysteine occurred immediately following the start of BNP7787 infusion, with the plasma thiol/disulfide nadir corresponding to the end of infusion. The mean half-life of cysteine depletion following BNP7787 administration was 2.2 h, significantly longer than for homocysteine (0.23 h), or GSH (0.18 h; P<0.05 for both). A several-fold increase in the urinary excretion of cysteine occurred following BNP7787 administration in all patients. The BNP7787-induced thiol/disulfide depletion in plasma was not affected by cisplatin administration ( P>0.05). BNP7787 administration had no effect on the ultrafilterable platinum pharmacokinetics. The 2-h lag in the depletion of cysteine, the most abundant thiol in plasma, suggests that the process may be related to the formation of free mesna from BNP7787 and that increased levels of mesna are not in circulation until after 2 h after BNP7787 administration. No effect of BNP7787 was seen on the GSH concentration in WBC, possibly reflecting the inability of these cells to take up BNP7787.The results suggest that BNP7787 has the potential to enhance cisplatin antitumor activity by depleting the reactive thiols in plasma.
结构式 | 名称/CAS号 | 分子式 | 全部文献 |
---|---|---|---|
![]() |
ω,ω'-乙二硫二磺酸
CAS:45127-11-5 |
C4H10O6S4 |
Mechanistic study of BNP7787-mediated cisplatin nephroprotec...
2011-02-01 [Cancer Chemother. Pharmacol. 67(2) , 381-91, (2011)] |
Phase II randomized study of dose-dense docetaxel and cispla...
2008-10-01 [J. Thorac. Oncol. 3(10) , 1159-65, (2008)] |
New approaches to drug discovery and development: a mechanis...
2003-07-01 [Cancer Chemother. Pharmacol. 52 Suppl 1 , S3-15, (2003)] |
Mechanistic study of BNP7787-mediated cisplatin nephroprotec...
2010-04-01 [Cancer Chemother. Pharmacol. 65(5) , 941-51, (2010)] |
Vibrational spectroscopic studies of mesna and dimesna.
2003-06-01 [Spectrochim. Acta. A. Mol. Biomol. Spectrosc. 59(8) , 1791-8, (2003)] |
首页 |
期刊大全 |
MSDS查询 |
化工产品分类 |
生物活性化合物 |
关于我们 |
免责声明:知识产权问题请联系 service1@chemsrc.com
Copyright © 2024 ChemSrc All Rights Reserved